SNDL SNDL Inc. IFRS Annual reports only
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1766600 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 946.40M | 920.45M | 909.01M | 712.20M | 56.13M |
| Cost of revenue | 687.75M | 680.12M | 718.59M | — | — |
| Gross profit | 258.65M | 240.33M | 190.41M | 140.38M | -9.00M |
| R&D expense | 489,000 | 346,000 | 324,000 | 2.45M | 2.45M |
| SG&A expense | 182.16M | 187.24M | 199.72M | 140.17M | 38.04M |
| Operating income | -6.35M | -103.81M | -163.17M | -347.77M | -134.38M |
| Interest expense | 6.69M | 7.16M | 11.36M | 178,000 | 40,000 |
| Pretax income | -15.77M | -105.61M | -172.02M | -379.77M | -234.70M |
| Net income | -15.77M | -94.80M | -172.66M | -335.11M | -226.98M |
| EBITDA | 45.60M | -49.56M | -102.95M | -306.83M | -129.09M |
| EPS (basic) | -0.06 | -0.36 | -0.67 | -1.46 | — |
| EPS (diluted) | -0.06 | -0.36 | -0.67 | -1.46 | — |
| Balance sheet | |||||
| Cash & equivalents | 252.24M | 218.36M | 195.04M | 279.59M | 558.25M |
| Short-term investments | 484,000 | 27.56M | 3.40M | 6.55M | 3.06M |
| Receivables | 24.10M | 24.55M | 20.85M | 17.56M | 10.87M |
| Inventory | 126.88M | 127.92M | 129.06M | 127.78M | 29.50M |
| Current assets | 449.62M | 461.84M | 406.91M | 501.48M | 728.17M |
| PP&E, netmay include right-of-use assets (IFRS) | 151.90M | 145.81M | 152.92M | 143.41M | 56.47M |
| Goodwill | 124.25M | 124.25M | 119.28M | 67.26M | 72.50M |
| Intangibles | 58.52M | 61.33M | 73.15M | 74.89M | 50.15M |
| Total assets | 1.34B | 1.35B | 1.47B | 1.56B | 1.43B |
| Current liabilities | 92.21M | 90.56M | 103.15M | 89.36M | 65.85M |
| Total liabilities | 234.72M | 215.89M | 243.82M | 231.69M | 98.13M |
| Shareholders' equity | 1.10B | 1.13B | 1.21B | 1.31B | 1.33B |
| Cash flow statement | |||||
| Operating cash flow | 70.92M | 54.91M | -16.65M | -6.71M | -155.75M |
| Capital expenditure | 12.81M | 8.62M | 7.84M | 10.67M | 3.79M |
| Free cash flow | 58.11M | 46.30M | -24.49M | -17.38M | -159.54M |
| Investing cash flow | 17.45M | 17.76M | -24.82M | -230.16M | -496.28M |
| Financing cash flow | -54.49M | -49.36M | -43.08M | -41.79M | 1.15B |
| Depreciation & amortization | 51.95M | 54.25M | 60.22M | 40.95M | 5.29M |
| Stock-based compensation | 13.90M | 20.04M | 15.40M | 9.67M | 12.31M |
| Share buybacks | 15.35M | 13.22M | 1.54M | 13.39M | 0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.